Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial CancerJ. Clin. Oncol 2020 Jun 17;[EPub Ahead of Print], J Vuky, AV Balar, D Castellano, PH O'Donnell, P Grivas, J Bellmunt, T Powles, D Bajorin, NM Hahn, MJ Savage, X Fang, JL Godwin, TL Frenkl, B Homet Moreno, R de Wit, ER Plimack
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.